Pulse Biosciences appoints Burke T. Barrett as CEO; Kevin Danahy becomes Chief Commercial Officer

PULSE BIOSCIENCES, INC.

Burke T. Barrett named President and CEO effective May 12, 2024; succeeds Kevin Danahy who becomes Chief Commercial Officer.
Barrett previously CEO of CardioFocus, led global commercial launch of atrial fibrillation laser-balloon ablation device.
Barrett receives options to purchase 1.4M shares at $7.45, half time-vested over 4 years, half upon $1B-$4B market cap milestones.
Danahy and CTO Darrin Uecker amend employment agreements to reduce severance salary continuation from 12 to 3 months (12 months post-change of control).

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Burke T. Barrett

President and Chief Executive Officer

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2024-05-12
Filed: May 15, 2024, 7:59 PM ET

The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024

Appointed

Burke T. Barrett

Director

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2024-05-12
Filed: May 15, 2024, 7:59 PM ET

The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024

Role change

Kevin P. Danahy

Chief Commercial Officer

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2024-05-12
Successor: Burke T. Barrett
Filed: May 15, 2024, 7:59 PM ET

Mr. Barrett succeeds Kevin P. Danahy, who was appointed as the Company’s Chief Commercial Officer, as of the Start Date

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Burke T. Barrett was appointed as President and Chief Executive Officer at PULSE BIOSCIENCES, INC..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Burke T. Barrett was appointed as Director at PULSE BIOSCIENCES, INC..

Action: appointed
Role: Director

Exact text from the filing

The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin P. Danahy was appointed as Chief Commercial Officer at PULSE BIOSCIENCES, INC..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

Mr. Barrett succeeds Kevin P. Danahy, who was appointed as the Company’s Chief Commercial Officer, as of the Start Date

View on SEC.gov

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-016821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.